These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 32559430)
21. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo. Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967 [TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
23. Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Fujiwara K; Tsunei A; Kusabuka H; Ogaki E; Tachibana M; Okada N Cells; 2020 May; 9(5):. PubMed ID: 32397414 [TBL] [Abstract][Full Text] [Related]
24. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide. Yang P; Wang Y; Yao Z; Gao X; Liu C; Wang X; Wu H; Ding X; Hu J; Lin B; Li Q; Li M; Li X; Chen X; Qi W; Li W; Xue J; Xu H J Am Chem Soc; 2020 Nov; 142(44):18874-18885. PubMed ID: 32966054 [TBL] [Abstract][Full Text] [Related]
34. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912 [TBL] [Abstract][Full Text] [Related]
35. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer. Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795 [TBL] [Abstract][Full Text] [Related]
36. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors. Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137 [No Abstract] [Full Text] [Related]
37. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Marcus A; Eshhar Z Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086 [TBL] [Abstract][Full Text] [Related]
38. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes. Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O Front Immunol; 2020; 11():1704. PubMed ID: 32849600 [TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066 [TBL] [Abstract][Full Text] [Related]
40. Establishing guidelines for CAR-T cells: challenges and considerations. Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]